Helen M. Thackray is Chief R&D Officer at BIOCRYST PHARMACEUTICALS INC (BCRX). They have made 7 open-market trades across 2 companies since 2016, most recently 2025-03-31.
CIK 0001589725
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $176K since 2024, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BCRX | BUY | 2024-05-14 | 2024-05-15 | $5.86 | $176K | -3.3% | -3.6% | +23.3% |
| BCRX | SELL · 10b5-1 | 2023-04-03 | 2023-04-05 | $8.29 | $116K | -12.4% | +0.0% | -17.8% |
| BCRX | SELL · 10b5-1 | 2022-12-15 | 2022-12-19 | $10.89 | $34K | +8.8% | -4.2% | -24.1% |
| BCRX | SELL | 2022-04-01 | 2022-04-04 | $16.20 | $123K | -31.0% | -38.3% | -32.5% |
| GLYC | SELL | 2017-12-08 | 2017-12-12 | $15.01 | $30K | +3.1% | +25.3% | +13.6% |
| GLYC | SELL | 2017-09-18 | 2017-09-18 | $13.00 | $26K | +2.6% | -20.2% | +17.0% |
| GLYC | SELL | 2017-05-25 | 2017-05-30 | $15.57 | $31K | -14.7% | -18.8% | -13.7% |
| GLYC | SELL · 10b5-1 | 2017-05-19 | 2017-05-22 | $12.14 | $24K | +17.5% | +10.3% | -7.8% |
| GLYC | SELL · 10b5-1 | 2016-10-03 | 2016-10-04 | $7.00 | $28K | -11.4% | -14.1% | -7.1% |
| GLYC | SELL · 10b5-1 | 2016-07-20 | 2016-07-21 | $8.00 | $16K | +4.2% | -2.8% | -22.1% |
| GLYC | SELL | 2016-07-05 | 2016-07-06 | $7.01 | $71K | +13.9% | +21.4% | -4.3% |
| GLYC | SELL | 2016-07-01 | 2016-07-06 | $7.00 | $154K | +13.9% | +21.4% | -4.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.